Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mad Scientists And Skunkworks Could Bring Back CNS Creativity, TAP Panelists Say

Executive Summary

“Everything that applies to pharma in general is magnified in neuroscience because the timelines are compressed and the punishment for failure is greater,” industry consultant Harry Tracy said at the Therapeutic Area Partnerships meeting.

You may also be interested in...



APA Takeaways: Former Sanofi Exec Reflects On DSM-5, Eroom’s Law And More

The recent American Psychiatric Association annual meeting featured a lecture on drug development by Sanofi’s former head of CNS development Robert Lenox. In a post-meeting interview, he weighs in on the highs and lows of psychiatric drug development, as well as the newly released fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.

Gloomy Neuroscience Partnering Outlook May Soon Brighten

At least two companies in the neuroscience space are set to deliver potentially good news by year’s end, with other promising candidates in the offing, according to industry consultant Harry Tracy, who compiled a list of the top 10 partnering opportunities in the field for the upcoming Therapeutic Area Partnerships meeting.

Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot

With the potential for a multi-billion-dollar blockbuster on its hands, Eli Lilly could conduct a confirmatory trial or even seek near-term approval of sola after pooled data revealed a hint of disease modifying potential in mildly affected Alzheimer’s patients, though the company also may be grasping at straws.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel